Compare American Airlines Group Inc (AAL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs DexCom, Inc. — how do they compare? American Airlines Group Inc trades at $15.02 (market cap $10.55B), while DexCom, Inc. trades at $89.39 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 3.2× American Airlines Group Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, American Airlines Group Inc nearer its low. Which is the better fit depends on your goals.
| AAL | DXCM | |
|---|---|---|
Market Cap | $10.55B | $33.79B |
Sector | Industrials | Health |
52-Week High | $18.15 | $89.53 |
52-Week Low | $10.18 | $54.84 |
Enterprise Value | $38.51B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.00, down 5.9% in the last 24 hours, with technical indicators signaling a bearish trend near support at $14. The company reported mixed earnings, beating estimates in Q1 and Q2 2026 but missing in Q4 2025, with revenue growth to $54.63 billion in 2025. However, net income margin remains negative at -0.56%, and high debt levels persist despite a declining trend.
AAL's outlook is cautious; while analyst consensus is a buy with a $19.63 price target, risks include volatile fuel costs, leverage, and thin profitability. The stock offers potential upside if premium revenue growth sustains, but investors face headwinds from operational margins and economic sensitivity.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
